CA1174284A - Body implantable lead - Google Patents
Body implantable leadInfo
- Publication number
- CA1174284A CA1174284A CA000385012A CA385012A CA1174284A CA 1174284 A CA1174284 A CA 1174284A CA 000385012 A CA000385012 A CA 000385012A CA 385012 A CA385012 A CA 385012A CA 1174284 A CA1174284 A CA 1174284A
- Authority
- CA
- Canada
- Prior art keywords
- drug
- lead
- electrode
- implantable lead
- body implantable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/0565—Electrode heads
- A61N1/0568—Electrode heads with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/057—Anchoring means; Means for fixing the head inside the heart
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Electrotherapy Devices (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A body implantable lead for the delivery of stimulation energy to a desired body site including a drug dispenser carried by the lead which retains a drug to be dispensed while allowing a dis-pensing of that drug at least adjacent the desired body stimulation site. The drug may be one which is intended to counter thrombus formation, fibrosis, inflammation or arrhythmias, or any combina-tion thereof, or to accomplish any other localized purpose. The drug may be in liquid form retained in a reservoir carried by the lead with an agency controlling dispensing of the drug. The con-trolling agency may be a semi-permeable membrane. Alternatively, the reservoir may be formed as an osmotic pump. As a further alternative, the drug may be retained as a coating on a large sur-face area portion of the lead, or an electrode carried by the lead.
In a preferred embodiment, the drug is compounded into a solid material which is carried by the lead while being exposed to body tissues and flesh or fluids at least adjacent the desired stimula-tion site.
A body implantable lead for the delivery of stimulation energy to a desired body site including a drug dispenser carried by the lead which retains a drug to be dispensed while allowing a dis-pensing of that drug at least adjacent the desired body stimulation site. The drug may be one which is intended to counter thrombus formation, fibrosis, inflammation or arrhythmias, or any combina-tion thereof, or to accomplish any other localized purpose. The drug may be in liquid form retained in a reservoir carried by the lead with an agency controlling dispensing of the drug. The con-trolling agency may be a semi-permeable membrane. Alternatively, the reservoir may be formed as an osmotic pump. As a further alternative, the drug may be retained as a coating on a large sur-face area portion of the lead, or an electrode carried by the lead.
In a preferred embodiment, the drug is compounded into a solid material which is carried by the lead while being exposed to body tissues and flesh or fluids at least adjacent the desired stimula-tion site.
Description
Electrical stimulation of the body for medical purposes is well known in the prior art. An example of a device for this purpose is the well-known cardiac pacemaker. In the pacemaker con-text, as well as other body stimulation contexts, the stimulation is delivered to the desired body site by an electrode carrying lead.
Interactions between the lead and body can vitiate the desired effects of the stimulation. For example, material reactions may encourage fibrosis. In the pacemaking context, fibrosis is believed to be a major factor in the increase in chronic threshold that is usually experienced. Also, mechanical trauma may result in inflammation of the tissue to be stimulated. Such inflammation may alter the response of the tissue to the stimulation energy, both acutely and chronically.
Other interactions between the lead and body, while not directly affecting the response of the tissue to the stimulation energy, can result in the occurrence of undesirable events~ In some circumstances where electrical body stimulation is indicated, the body portion to be stimulated is irritable. The placement of a lead may compound this irritability. For example, the placement of a pacemaking lead may induce a cardiac arrhythmia. The presence of the`lead may also promote thrombus formation.
The interactions noted above have long been recognized and efforts made to ameliorate their consequences. For example, the lead may be configured to reduce mechanical trauma and the response of irritable tissue during lead placement. Materials may be selected for the lead body and electrodes to minimize fibrosis.
Thrombus formation may also be countered by the administration of suitable drugs. It is also known that a systemic treatment with steroids results in acute reduction in the threshold level.
The administration oE drugs ko counter the undesirable interactions between the lead and body noted above has not gained widespread acceptance in that it has heretofore required a systemic treatment to counter a localized interaction. Also, lead configuration must take into account other factors such as the efficiency of the del;very of the stimulation energy, the ease of lead placement, maintenance of the desired electrode posit;on and reliability of the lead over extended periods of time. An accommodation of these interests has resulted in leads whose con-figuration necessarily results in undesirable interactions between the lead and body.
The present invention provides a body implantable lead for the delivery of stimulation energy to a desired body site which may be configured and constructed in accordance with known techniques while amellorating the effects of undesirable inter-actions between the lead and body. A drug dispenser is carried by the lead and ~ncludes a member for retaining the drug to be dispensed while allowing a dispensing of that drug at least adjacent the desired body stimulation site. The drug may be one intended to counter thrombus formation, fibrosis, inflammation, or arrhythmias, or any combination thereof, or to accomplish any other desirable localized purpose. The drug may be retained in liqu;d form in a reservoir including an asency for controlling the dispensing of the drug. The agency may be a semi-permeable mem-brane or, alternatively, the reservoir may be formed as an osmotic .:
pump. The drug may be carried as a coa~ing on a high surface area portion of the lead, or an electrode carried by the lead. In a preEerred embodiment, the drug is compounded into a solid material with that solid material being carried by the leacl adjacent the electrode. Most preEerably, the lead carries a tip electrode at its distal end with the drug being dispensed through the tip ele-ctrode.
Thus, in accordance with a broad aspect o the invention, there is provided, in a body implantable lead for the delivery oE stimulation energy to a desired body site of the type having at least one electrode carried by the lead, said electrode being adapted for positioning at least adjacent said body site, the improvement wherein said lead further comprises drug dispenser means for retaining a drug which counters inElammation while allowing a dispensing of said drug at least adjacent said electrode.
The invention will now be further described in conjunction with the accompanying drawings, in which:
Figure 1 illustrates a portion oE a body implantable lead constructed in accordance with a preferred embodiment of the present invention.
Figure 2 illustrates a cross-section taken along the line 2-2 in Figure 1.
Figure 3 illustrates the configuration of a portion of a lead constructed in accordance with the preferred embodiments illustrated in Fig-ures 4-6.
Figures 4-6 illustrate alternative preferred embodiments viewed along the line 4-4 in Figure 3.
.~
21~
Figure 1 illustrates a portion of a lead constructed in accordance with a preferred embodiment of the present invention including a lead body 10 formed of a conductor 11 and insulating sheath 12 and carrying at its distal end a tip electrode 13.
The conductor 11 extends between the tip electrode 13 and a source of stimulation energy, in known manner. In the illustrated embodi-ment, the conductor 11 is formed as a helically wound conductor, also in known manner. A drug dispenser indicated generally at 14 is carried by the lead and has tines 15 extendin~ therefrom. Tines 15 are of known design and form no part of the present invention aside from forming a portion of the disclosed preferred embodiments thereof.
Figure 2 is a cross-section taken along the line 2-2 in Figure 1 and illustrates drug dispenser 14 as an osmotic pump of generally known design. Pump 14 has inner and outer chambers 16 and 17, respectively, separated by an impermeable membrane 18.
A semi-permeable membrane 19 forms the outer wall of chamber 17 while an extension 20 of electrode 13 extends into the chamber 16.
As is apparent to those skilled in the art, the electrode 13 and its extension 20 are formed of a conductive material.
The conductor 11 extends from the lead body 10 into the chamber 16 and into electrical communication with the extension 20 of electrode 13. The extension 20 of electrode 13 may be crimped as at 21 to maintain the electrical communication between it and the conductor 11. A seal 22 is provided in the chamber walls 18 and 19 at the point at ~hich the conductor 11 passes through them. An end cap 23 closes the chamber 16.
_ ~ _ ~.t'~
Prior to implantation, the chamber 16 is charged with a drug to be dispensecl. The drug may be any suitable drug in-tended to accomplish any desirable localized purpose. For example, the drug may be one intended to counter thrombus formation, fibrosis, inflammation, or arrhythmias, or any comhination of drugs intended to accomplish one or more o~ those purposes, or any drug or combination of drugs intended to accomplish any other desirable localized purpose or purposes. The chamber 16 is charged through the extension 20 of electrode 13 with the drug passing into the chamber 16 between the coils of conductor 11 at the location between the end of the extension 20 o~ the electrode 13 and the seal 22. After the chamber 16 is charged and the lead implanted, body fluids will enter the chamber 17 through the semi-permeable membrane 19 to impart a pressure on the chamber 16 via th.e impermeable membrane 18. This will result in a dispensing of the drug with.in the chamber 16 through the extension 20 of the electrode 13, and the electrode 13.
Figure 3 illustrates the outward configuration of a portion of a lead constructed in accordance with the preferred embodiments of Figures 4-6. Throughout the figures, like reference numerals i.ndicate like elements including lead body 10, formed of conductor 11 and sheath 12, and tines 15. A distal tip electrode 13 is ind.;cated generally at 13 in Figure 3 as is a drug dispenser 14.
Referring now to Figure 4, there ;s illustrated a pre-ferred embodiment of the present inventi.on as viewed along the line 4-4 in Figure 3. A tip electrode 13' is carried at the distal end `~ 15 4 of the lead and has a central bore which is filled with a solid material 24 which will be discussed more fully below. The electrode 13' extends from the distal end of the lead into electrical comm~mication with the conductor 11. Electrical com-munication between the electrode 13' and conductor 11 may be established and maintained in any known manner.
Material 24 within the central bore in electrode 13' is a complete material formed by compounding the drug to be dis-pensed, in solid form, with a solid material suitable for use as a carrier so as to form a permeable structure that allows the body fluids to enter and extract the compounded drug. For this purpose, the compounded drug must be water soluble. The carrier material may be a suitable silicone that is compounded with the drug to be dispensed and then placed in the central bore in the electrode 13'.
The drug may be dispensed through the electrode 13' from the central bore of the electrode 13'. Additionally, ports may be ~rov~ded between the central bore of electrode 13' to the sheath of the lead or side of the electrode as indicated at 25 to provide addition-al dispensing locations adjacent the electrode 13'. Alternatively, 2Q the central bore through the electrode 13' may be plugged ~ith the d;spensing ~eing accomplished through the ports ~5. Any number of ports 25 may be employed.
Figure 5 illustrates yet another preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3.
In the embodiment of Figure 5, a tip electrode 13" again has a central ~ore. However, in the embodiment of Figure 5 that bore is closed by a semi-permea~le membrane 26. Closing of the bore in electrode 13" by the membrane 26 forms a reservoir 27 within the bore. An access port 28 is provided through the sidewall of the sheath to allow access to the reservoir 27. The member forming the access port 28 may be a self-sealiny material such as silicone ru~ber which may ~e penetrated, as by a syringe, to charge the reservoir 27 while sealing the puncture from the syringe on with-drawal, in known manner. The reservoir 27 may be charged with any suitable drug that it is desired to dispense and which has a molecular structure that will allow passage through the semi-permeable membrane to be dispensed by diffusion, in known manner.
Figure 6 illustrates yet another preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3.
In Figure 6, the electrode 13"' is formed of a sintered material, titanium, for example. Sintering of the electrods material pro-vides a high surface area on which the drug to be dispensed may be deposited as a coating. The sintered electrode may be coated with the drug to be dispensed at the time of manufacture. Alternatively, the coating may be selectively applied at or prior to the time of implant of the lead.
Obviously, many modifications and vari~ations of the present invention are possible in light of th~e above teachings.
For example, Flgure 4 discloses an embodiment wherein the drug to be dispensed is compounded so as to form a composite material.
That same process may be employed to form a cc~posite material which may be employed to form the sheath 12 of the lead, the tines 15 or both. Also, while druys to accomplish specific purposes are discussed herein, the ïnvention is not limited to drugs that are 1'i'~Li2~
useful to accomplish only those purposes. Further, apart from forming a part of the delivery system for the electrical stimu-lation energy, the particular conductor and sheath configurations form no part o the present invention. Indeed, the disclosed electrode configurations may be varied without departing from the scope o the present invention. It is therefore to be under-stood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
- 8~ ~
Interactions between the lead and body can vitiate the desired effects of the stimulation. For example, material reactions may encourage fibrosis. In the pacemaking context, fibrosis is believed to be a major factor in the increase in chronic threshold that is usually experienced. Also, mechanical trauma may result in inflammation of the tissue to be stimulated. Such inflammation may alter the response of the tissue to the stimulation energy, both acutely and chronically.
Other interactions between the lead and body, while not directly affecting the response of the tissue to the stimulation energy, can result in the occurrence of undesirable events~ In some circumstances where electrical body stimulation is indicated, the body portion to be stimulated is irritable. The placement of a lead may compound this irritability. For example, the placement of a pacemaking lead may induce a cardiac arrhythmia. The presence of the`lead may also promote thrombus formation.
The interactions noted above have long been recognized and efforts made to ameliorate their consequences. For example, the lead may be configured to reduce mechanical trauma and the response of irritable tissue during lead placement. Materials may be selected for the lead body and electrodes to minimize fibrosis.
Thrombus formation may also be countered by the administration of suitable drugs. It is also known that a systemic treatment with steroids results in acute reduction in the threshold level.
The administration oE drugs ko counter the undesirable interactions between the lead and body noted above has not gained widespread acceptance in that it has heretofore required a systemic treatment to counter a localized interaction. Also, lead configuration must take into account other factors such as the efficiency of the del;very of the stimulation energy, the ease of lead placement, maintenance of the desired electrode posit;on and reliability of the lead over extended periods of time. An accommodation of these interests has resulted in leads whose con-figuration necessarily results in undesirable interactions between the lead and body.
The present invention provides a body implantable lead for the delivery of stimulation energy to a desired body site which may be configured and constructed in accordance with known techniques while amellorating the effects of undesirable inter-actions between the lead and body. A drug dispenser is carried by the lead and ~ncludes a member for retaining the drug to be dispensed while allowing a dispensing of that drug at least adjacent the desired body stimulation site. The drug may be one intended to counter thrombus formation, fibrosis, inflammation, or arrhythmias, or any combination thereof, or to accomplish any other desirable localized purpose. The drug may be retained in liqu;d form in a reservoir including an asency for controlling the dispensing of the drug. The agency may be a semi-permeable mem-brane or, alternatively, the reservoir may be formed as an osmotic .:
pump. The drug may be carried as a coa~ing on a high surface area portion of the lead, or an electrode carried by the lead. In a preEerred embodiment, the drug is compounded into a solid material with that solid material being carried by the leacl adjacent the electrode. Most preEerably, the lead carries a tip electrode at its distal end with the drug being dispensed through the tip ele-ctrode.
Thus, in accordance with a broad aspect o the invention, there is provided, in a body implantable lead for the delivery oE stimulation energy to a desired body site of the type having at least one electrode carried by the lead, said electrode being adapted for positioning at least adjacent said body site, the improvement wherein said lead further comprises drug dispenser means for retaining a drug which counters inElammation while allowing a dispensing of said drug at least adjacent said electrode.
The invention will now be further described in conjunction with the accompanying drawings, in which:
Figure 1 illustrates a portion oE a body implantable lead constructed in accordance with a preferred embodiment of the present invention.
Figure 2 illustrates a cross-section taken along the line 2-2 in Figure 1.
Figure 3 illustrates the configuration of a portion of a lead constructed in accordance with the preferred embodiments illustrated in Fig-ures 4-6.
Figures 4-6 illustrate alternative preferred embodiments viewed along the line 4-4 in Figure 3.
.~
21~
Figure 1 illustrates a portion of a lead constructed in accordance with a preferred embodiment of the present invention including a lead body 10 formed of a conductor 11 and insulating sheath 12 and carrying at its distal end a tip electrode 13.
The conductor 11 extends between the tip electrode 13 and a source of stimulation energy, in known manner. In the illustrated embodi-ment, the conductor 11 is formed as a helically wound conductor, also in known manner. A drug dispenser indicated generally at 14 is carried by the lead and has tines 15 extendin~ therefrom. Tines 15 are of known design and form no part of the present invention aside from forming a portion of the disclosed preferred embodiments thereof.
Figure 2 is a cross-section taken along the line 2-2 in Figure 1 and illustrates drug dispenser 14 as an osmotic pump of generally known design. Pump 14 has inner and outer chambers 16 and 17, respectively, separated by an impermeable membrane 18.
A semi-permeable membrane 19 forms the outer wall of chamber 17 while an extension 20 of electrode 13 extends into the chamber 16.
As is apparent to those skilled in the art, the electrode 13 and its extension 20 are formed of a conductive material.
The conductor 11 extends from the lead body 10 into the chamber 16 and into electrical communication with the extension 20 of electrode 13. The extension 20 of electrode 13 may be crimped as at 21 to maintain the electrical communication between it and the conductor 11. A seal 22 is provided in the chamber walls 18 and 19 at the point at ~hich the conductor 11 passes through them. An end cap 23 closes the chamber 16.
_ ~ _ ~.t'~
Prior to implantation, the chamber 16 is charged with a drug to be dispensecl. The drug may be any suitable drug in-tended to accomplish any desirable localized purpose. For example, the drug may be one intended to counter thrombus formation, fibrosis, inflammation, or arrhythmias, or any comhination of drugs intended to accomplish one or more o~ those purposes, or any drug or combination of drugs intended to accomplish any other desirable localized purpose or purposes. The chamber 16 is charged through the extension 20 of electrode 13 with the drug passing into the chamber 16 between the coils of conductor 11 at the location between the end of the extension 20 o~ the electrode 13 and the seal 22. After the chamber 16 is charged and the lead implanted, body fluids will enter the chamber 17 through the semi-permeable membrane 19 to impart a pressure on the chamber 16 via th.e impermeable membrane 18. This will result in a dispensing of the drug with.in the chamber 16 through the extension 20 of the electrode 13, and the electrode 13.
Figure 3 illustrates the outward configuration of a portion of a lead constructed in accordance with the preferred embodiments of Figures 4-6. Throughout the figures, like reference numerals i.ndicate like elements including lead body 10, formed of conductor 11 and sheath 12, and tines 15. A distal tip electrode 13 is ind.;cated generally at 13 in Figure 3 as is a drug dispenser 14.
Referring now to Figure 4, there ;s illustrated a pre-ferred embodiment of the present inventi.on as viewed along the line 4-4 in Figure 3. A tip electrode 13' is carried at the distal end `~ 15 4 of the lead and has a central bore which is filled with a solid material 24 which will be discussed more fully below. The electrode 13' extends from the distal end of the lead into electrical comm~mication with the conductor 11. Electrical com-munication between the electrode 13' and conductor 11 may be established and maintained in any known manner.
Material 24 within the central bore in electrode 13' is a complete material formed by compounding the drug to be dis-pensed, in solid form, with a solid material suitable for use as a carrier so as to form a permeable structure that allows the body fluids to enter and extract the compounded drug. For this purpose, the compounded drug must be water soluble. The carrier material may be a suitable silicone that is compounded with the drug to be dispensed and then placed in the central bore in the electrode 13'.
The drug may be dispensed through the electrode 13' from the central bore of the electrode 13'. Additionally, ports may be ~rov~ded between the central bore of electrode 13' to the sheath of the lead or side of the electrode as indicated at 25 to provide addition-al dispensing locations adjacent the electrode 13'. Alternatively, 2Q the central bore through the electrode 13' may be plugged ~ith the d;spensing ~eing accomplished through the ports ~5. Any number of ports 25 may be employed.
Figure 5 illustrates yet another preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3.
In the embodiment of Figure 5, a tip electrode 13" again has a central ~ore. However, in the embodiment of Figure 5 that bore is closed by a semi-permea~le membrane 26. Closing of the bore in electrode 13" by the membrane 26 forms a reservoir 27 within the bore. An access port 28 is provided through the sidewall of the sheath to allow access to the reservoir 27. The member forming the access port 28 may be a self-sealiny material such as silicone ru~ber which may ~e penetrated, as by a syringe, to charge the reservoir 27 while sealing the puncture from the syringe on with-drawal, in known manner. The reservoir 27 may be charged with any suitable drug that it is desired to dispense and which has a molecular structure that will allow passage through the semi-permeable membrane to be dispensed by diffusion, in known manner.
Figure 6 illustrates yet another preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3.
In Figure 6, the electrode 13"' is formed of a sintered material, titanium, for example. Sintering of the electrods material pro-vides a high surface area on which the drug to be dispensed may be deposited as a coating. The sintered electrode may be coated with the drug to be dispensed at the time of manufacture. Alternatively, the coating may be selectively applied at or prior to the time of implant of the lead.
Obviously, many modifications and vari~ations of the present invention are possible in light of th~e above teachings.
For example, Flgure 4 discloses an embodiment wherein the drug to be dispensed is compounded so as to form a composite material.
That same process may be employed to form a cc~posite material which may be employed to form the sheath 12 of the lead, the tines 15 or both. Also, while druys to accomplish specific purposes are discussed herein, the ïnvention is not limited to drugs that are 1'i'~Li2~
useful to accomplish only those purposes. Further, apart from forming a part of the delivery system for the electrical stimu-lation energy, the particular conductor and sheath configurations form no part o the present invention. Indeed, the disclosed electrode configurations may be varied without departing from the scope o the present invention. It is therefore to be under-stood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
- 8~ ~
Claims (11)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. In a body implantable lead for the delivery of stimulation energy to a desired body site of the type having at least one electrode carried by the lead, said electrode being adapted for positioning at least adjacent said body site, the improvement wherein said lead further comprises drug dispenser means for retaining a drug which counters inflammation while allowing a dis-pensing of said drug at least adjacent said electrode.
2. A body implantable lead as claimed in claim 1 wherein said drug dispenser means comprises reservoir means, said drug being in liquid form and said reservoir means comprising means for controlling the dispensing of said drug.
3. A body implantable lead as claimed in claim 2 wherein said drug dispensing controlling means comprises semi-permeable membrane means.
4. A body implantable lead as claimed in claim 2 wherein said reser-voir means and drug dispensing controlling means form osmotic pump means.
5. A body implantable lead as claimed in claim 1 wherein said electrode is formed of a sintered, conductive material, said drug being retained as a coating on said electrode.
6. A body implantable lead as claimed in claim 1 wherein said drug is compounded into a solid material, said solid material being carried by said lead adjacent said distal end.
7. A body implantable lead as claimed in claim 6 wherein said solid material forms at least a portion of the body of said lead.
8. A body implantable lead as claimed in claim 1 wherein said electrode comprises a distal tip electrode, said drug being dispensed through said tip electrode.
9. A body implantable lead as claimed in claim 1 wherein said electrode comprises a distal tip electrode, said drug being dispensed at least adjacent said tip electrode.
10. A body implantable lead as claimed in claim 9 wherein said drug is dispensed through said tip electrode.
11. A body implantable lead as claimed in claim 10 wherein said drug is compounded into a solid material, said solid material being carried by said lead at least partially within said tip electrode.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18296380A | 1980-09-02 | 1980-09-02 | |
US182,963 | 1988-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1174284A true CA1174284A (en) | 1984-09-11 |
Family
ID=22670818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000385012A Expired CA1174284A (en) | 1980-09-02 | 1981-09-01 | Body implantable lead |
Country Status (5)
Country | Link |
---|---|
US (1) | US4711251B1 (en) |
EP (1) | EP0047013B1 (en) |
JP (1) | JPS625174Y2 (en) |
CA (1) | CA1174284A (en) |
DE (1) | DE3173564D1 (en) |
Families Citing this family (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4506680A (en) * | 1983-03-17 | 1985-03-26 | Medtronic, Inc. | Drug dispensing body implantable lead |
US4606118A (en) * | 1985-02-27 | 1986-08-19 | Medtronic, Inc. | Method of making a drug dispensing body |
US4577642A (en) * | 1985-02-27 | 1986-03-25 | Medtronic, Inc. | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication |
DE3528878A1 (en) * | 1985-08-12 | 1987-02-19 | Sanden Hasko Von Dipl Ing Dr M | INTRAPERITONEAL CATHETER FOR THE INPUT OF LIQUID MEDICINAL PRODUCTS, IN PARTICULAR INSULIN |
US4844099A (en) * | 1986-11-24 | 1989-07-04 | Telectronics, N.V. | Porous pacemaker electrode tip using a porous substrate |
US4784161A (en) * | 1986-11-24 | 1988-11-15 | Telectronics, N.V. | Porous pacemaker electrode tip using a porous substrate |
FR2616072B1 (en) * | 1987-06-04 | 1990-12-14 | Ela Medical Sa | IMPROVEMENTS AT THE CONDUCTIVE END OF CARDIAC STIMULATION PROBES |
DE3735137A1 (en) * | 1987-10-16 | 1989-05-03 | Siemens Ag | ARRANGEMENT FOR DISPENSING MEDICINES IN AN IMPLANTABLE MEDICAL DEVICE |
US4819662A (en) * | 1987-10-26 | 1989-04-11 | Cardiac Pacemakers, Inc. | Cardiac electrode with drug delivery capabilities |
US4819661A (en) * | 1987-10-26 | 1989-04-11 | Cardiac Pacemakers, Inc. | Positive fixation cardiac electrode with drug elution capabilities |
US4947842A (en) * | 1988-09-22 | 1990-08-14 | Medical Engineering And Development Institute, Inc. | Method and apparatus for treating tissue with first and second modalities |
US6146358A (en) | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
EP0388480A1 (en) * | 1989-03-20 | 1990-09-26 | Siemens Aktiengesellschaft | Implantable stimulation electrode |
WO1990012611A1 (en) * | 1989-04-21 | 1990-11-01 | Ash Medical Systems, Inc. | Non-intravascular infusion access device |
US4972848A (en) * | 1989-08-23 | 1990-11-27 | Medtronic, Inc. | Medical electrical lead with polymeric monolithic controlled release device and method of manufacture |
US5003992A (en) * | 1989-08-23 | 1991-04-02 | Holleman Timothy W | Atraumatic screw-in lead |
US4953564A (en) * | 1989-08-23 | 1990-09-04 | Medtronic, Inc. | Screw-in drug eluting lead |
US5002067A (en) * | 1989-08-23 | 1991-03-26 | Medtronic, Inc. | Medical electrical lead employing improved penetrating electrode |
US5020544A (en) * | 1989-11-01 | 1991-06-04 | Cardiac Pacemakers, Inc. | Low energy defibrillation electrode |
US5217028A (en) * | 1989-11-02 | 1993-06-08 | Possis Medical, Inc. | Bipolar cardiac lead with drug eluting device |
US5255693A (en) * | 1989-11-02 | 1993-10-26 | Possis Medical, Inc. | Cardiac lead |
US5086787A (en) * | 1989-12-06 | 1992-02-11 | Medtronic, Inc. | Steroid eluting intramuscular lead |
US5009229A (en) * | 1989-12-06 | 1991-04-23 | Medtronic, Inc. | Steroid eluting intramuscular lead |
US5049132A (en) * | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
US5111812A (en) * | 1990-01-23 | 1992-05-12 | Cardiac Pacemakers, Inc. | Defilbrillation electrode having smooth current distribution |
US5092332A (en) * | 1990-02-22 | 1992-03-03 | Medtronic, Inc. | Steroid eluting cuff electrode for peripheral nerve stimulation |
US5265608A (en) * | 1990-02-22 | 1993-11-30 | Medtronic, Inc. | Steroid eluting electrode for peripheral nerve stimulation |
US5081990A (en) * | 1990-05-11 | 1992-01-21 | New York University | Catheter for spinal epidural injection of drugs and measurement of evoked potentials |
US5282844A (en) * | 1990-06-15 | 1994-02-01 | Medtronic, Inc. | High impedance, low polarization, low threshold miniature steriod eluting pacing lead electrodes |
US5087243A (en) * | 1990-06-18 | 1992-02-11 | Boaz Avitall | Myocardial iontophoresis |
EP0491082B1 (en) * | 1990-12-19 | 1995-04-12 | Peter Dr. Ing. Osypka | Pacemaker lead with an inner duct and with an electrode head |
US5154182A (en) * | 1991-02-15 | 1992-10-13 | Siemens Pacesetter, Inc. | Drug or steroid releasing patch electrode for an implantable arrhythmia treatment system |
US5243977A (en) * | 1991-06-26 | 1993-09-14 | Trabucco Hector O | Pacemaker |
US5324325A (en) * | 1991-06-27 | 1994-06-28 | Siemens Pacesetter, Inc. | Myocardial steroid releasing lead |
SE9102778D0 (en) * | 1991-09-25 | 1991-09-25 | Siemens Elema Ab | IMPLANT MEDICAL DEVICE |
US5385541A (en) * | 1992-04-24 | 1995-01-31 | Loma Linda University Medical Center | Cerebrospinal fluid shunt capable of minimal invasive revision |
FR2690626B1 (en) * | 1992-04-30 | 1998-10-16 | Ela Medical Sa | PROBE FOR HEART STIMULATOR. |
US5318572A (en) * | 1992-06-02 | 1994-06-07 | Siemens Pacesetter, Inc. | High efficiency tissue stimulating and signal sensing electrode |
FR2693115B1 (en) * | 1992-07-02 | 1994-08-19 | Celsa Lg | Implantable electrical conductor and stimulation set, particularly for the heart. |
US5447533A (en) * | 1992-09-03 | 1995-09-05 | Pacesetter, Inc. | Implantable stimulation lead having an advanceable therapeutic drug delivery system |
US5324324A (en) * | 1992-10-13 | 1994-06-28 | Siemens Pacesetter, Inc. | Coated implantable stimulation electrode and lead |
US5330525A (en) * | 1993-04-29 | 1994-07-19 | Medtronic, Inc. | Epicardial lead having dual rotatable anchors |
US5408744A (en) * | 1993-04-30 | 1995-04-25 | Medtronic, Inc. | Substrate for a sintered electrode |
WO1995011723A1 (en) * | 1993-10-29 | 1995-05-04 | Medtronic, Inc. | Method of manufacturing a medical electrical lead |
US5397343A (en) * | 1993-12-09 | 1995-03-14 | Medtronic, Inc. | Medical electrical lead having counter fixation anchoring system |
US5423876A (en) * | 1993-12-09 | 1995-06-13 | Medtronic, Inc. | Intramuscular lead having improved insertion |
US5489294A (en) * | 1994-02-01 | 1996-02-06 | Medtronic, Inc. | Steroid eluting stitch-in chronic cardiac lead |
US5443492A (en) * | 1994-02-02 | 1995-08-22 | Medtronic, Inc. | Medical electrical lead and introducer system for implantable pulse generator |
US5496360A (en) * | 1994-04-12 | 1996-03-05 | Ventritex, Inc. | Implantable cardiac electrode with rate controlled drug delivery |
US5545207A (en) * | 1994-08-24 | 1996-08-13 | Medtronic, Inc. | Medical electrical lead having stable fixation system |
US5582591A (en) * | 1994-09-02 | 1996-12-10 | Delab | Delivery of solid drug compositions |
US5837276A (en) * | 1994-09-02 | 1998-11-17 | Delab | Apparatus for the delivery of elongate solid drug compositions |
US5562723A (en) * | 1994-10-06 | 1996-10-08 | Medtronic, Inc. | Medical electrical lead having a reinforced tine assembly |
US5741319A (en) * | 1995-01-27 | 1998-04-21 | Medtronic, Inc. | Biocompatible medical lead |
US5704915A (en) * | 1995-02-14 | 1998-01-06 | Therex Limited Partnership | Hemodialysis access device |
US5871484A (en) * | 1995-11-09 | 1999-02-16 | General Orthopedics | Apparatus and method for administering a biologically active substance to a bone |
US6051017A (en) | 1996-02-20 | 2000-04-18 | Advanced Bionics Corporation | Implantable microstimulator and systems employing the same |
US5987746A (en) * | 1996-02-21 | 1999-11-23 | Medtronic, Inc. | Method of making medical electrical lead |
US6110155A (en) * | 1996-04-30 | 2000-08-29 | Medtronic, Inc. | Anti-inflammatory-agent-loaded catheter and method for preventing tissue fibrosis |
AU2458597A (en) | 1996-07-17 | 1998-02-09 | Medtronic, Inc. | System for genetically treating cardiac conduction disturbances |
WO1998002040A1 (en) | 1996-07-17 | 1998-01-22 | Medtronic, Inc. | System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
WO1998015317A1 (en) | 1996-10-07 | 1998-04-16 | Sulzer Intermedics Inc. | Controllable drug injection electrode |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US6741877B1 (en) * | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
EP0984813A1 (en) * | 1997-05-13 | 2000-03-15 | Stuart D. Edwards | Global medical treatment method and apparatus |
US6477423B1 (en) * | 1997-05-28 | 2002-11-05 | Transneuronix, Inc. | Medical device for use in laparoscopic surgery |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6038482A (en) * | 1998-10-30 | 2000-03-14 | Pacesetter, Inc. | Open bore electrode with a tiered drug therapy delivery system |
US6395208B1 (en) | 1999-01-25 | 2002-05-28 | Atrium Medical Corporation | Method of making an expandable fluoropolymer device |
US7637886B2 (en) | 1999-01-25 | 2009-12-29 | Atrium Medical Corporation | Expandable fluoropolymer device and method of making |
US6955661B1 (en) | 1999-01-25 | 2005-10-18 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
US6304786B1 (en) * | 1999-03-29 | 2001-10-16 | Cardiac Pacemakers, Inc. | Implantable lead with dissolvable coating for improved fixation and extraction |
US6351668B1 (en) | 1999-05-07 | 2002-02-26 | Cedars-Sinai Medical Center | Method for inducing ventricular arrhythmias in an animal model system |
WO2001008717A1 (en) * | 1999-08-03 | 2001-02-08 | Smith & Nephew, Inc. | Controlled release implantable devices |
US6363287B1 (en) | 1999-10-27 | 2002-03-26 | Medtronic, Inc. | Steroid elution electrodes LVCV, left atrial medical/elecrical leads |
US6464688B1 (en) | 2000-02-15 | 2002-10-15 | Microsolutions, Inc. | Osmotic pump delivery system with flexible drug compartment |
US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US7840271B2 (en) | 2000-09-27 | 2010-11-23 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US7616997B2 (en) | 2000-09-27 | 2009-11-10 | Kieval Robert S | Devices and methods for cardiovascular reflex control via coupled electrodes |
US7499742B2 (en) | 2001-09-26 | 2009-03-03 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US8086314B1 (en) | 2000-09-27 | 2011-12-27 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US7623926B2 (en) | 2000-09-27 | 2009-11-24 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US6567704B2 (en) | 2000-12-20 | 2003-05-20 | Medtronic, Inc. | Medical electrical lead and method of use |
US6510348B2 (en) | 2000-12-20 | 2003-01-21 | Medtronic, Inc. | Perfusion lead and method of use |
WO2002053225A2 (en) | 2000-12-29 | 2002-07-11 | Medtronic, Inc. | Electrode system for stimulating the left heart chamber |
US6934589B2 (en) | 2000-12-29 | 2005-08-23 | Medtronic, Inc. | System and method for placing endocardial leads |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
SE0101154D0 (en) * | 2001-03-29 | 2001-03-29 | St Jude Medical | An electrically conductive lead and a method of producing such a lead |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6632217B2 (en) * | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
US20040236377A1 (en) * | 2001-07-02 | 2004-11-25 | Medtronic, Inc. | System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6999819B2 (en) | 2001-08-31 | 2006-02-14 | Medtronic, Inc. | Implantable medical electrical stimulation lead fixation method and apparatus |
US6671562B2 (en) | 2001-11-09 | 2003-12-30 | Oscor Inc. | High impedance drug eluting cardiac lead |
US6978185B2 (en) * | 2001-11-09 | 2005-12-20 | Oscor Inc. | Multifilar conductor for cardiac leads |
WO2003046504A1 (en) | 2001-11-26 | 2003-06-05 | Sielte S.P.A. | System and method for monitoring optical fiber cables |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
WO2003082403A2 (en) | 2002-03-27 | 2003-10-09 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control via coupled electrodes |
US7177704B2 (en) * | 2002-04-29 | 2007-02-13 | Medtronic, Inc. | Pacing method and apparatus |
US6978178B2 (en) * | 2002-04-30 | 2005-12-20 | Medtronic, Inc. | Method and apparatus for selecting an optimal electrode configuration of a medical electrical lead having a multiple electrode array |
US7226978B2 (en) * | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US6910579B2 (en) | 2002-05-28 | 2005-06-28 | Georgia-Pacific Corporation | Refillable flexible sheet dispenser |
US7082335B2 (en) * | 2002-09-30 | 2006-07-25 | Medtronic, Inc. | Multipolar pacing method and apparatus |
US7363244B2 (en) * | 2002-11-08 | 2008-04-22 | Palo Alto Research Center Incorporated | Methods, apparatus, and program products for inferring service usage |
US20040102830A1 (en) * | 2002-11-22 | 2004-05-27 | Williams Terrell M. | System for coupling an implanatable medical device to an epicardial site |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7925321B2 (en) | 2003-08-01 | 2011-04-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US20100168657A1 (en) | 2003-08-01 | 2010-07-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US6931327B2 (en) | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7953499B2 (en) * | 2003-09-30 | 2011-05-31 | Cardiac Pacemakers, Inc. | Drug-eluting electrode |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
WO2005051451A2 (en) * | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8774886B2 (en) | 2006-10-04 | 2014-07-08 | Dexcom, Inc. | Analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
EP2239566B1 (en) | 2003-12-05 | 2014-04-23 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
WO2005057175A2 (en) | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8099174B1 (en) | 2004-03-05 | 2012-01-17 | Pacesetter, Inc. | Left heart implantable cardiac stimulation system with clot prevention electrode body coating and method |
US7526336B2 (en) * | 2004-03-05 | 2009-04-28 | Pacesetter, Inc. | Left heart implantable cardiac stimulation system with clot prevention and method |
US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7720550B2 (en) * | 2004-12-03 | 2010-05-18 | Medtronic, Inc. | High impedance active fixation electrode of an electrical medical lead |
US20060240060A1 (en) * | 2005-04-22 | 2006-10-26 | Cardiac Pacemakers, Inc. | Lubricious compound and medical device made of the same |
US20060240059A1 (en) * | 2005-04-22 | 2006-10-26 | Cardiac Pacemakers, Inc. | Lubricious eluting polymer blend and coating made from the same |
US20060240253A1 (en) * | 2005-04-22 | 2006-10-26 | Cardiac Pacemakers, Inc. | Guidewire and tube with lubricious coating |
US20060241000A1 (en) * | 2005-04-22 | 2006-10-26 | Cardiac Pacemakers, Inc. | Lubricious compound and medical device made of the same |
US7974710B2 (en) * | 2005-04-28 | 2011-07-05 | Medtronic, Inc. | Guide catheters for accessing cardiac sites |
US20060247750A1 (en) * | 2005-04-28 | 2006-11-02 | Seifert Kevin R | Guide catheters for accessing cardiac sites |
US20070100411A1 (en) * | 2005-10-27 | 2007-05-03 | Medtronic, Inc. | Implantable medical electrical stimulation lead fixation method and apparatus |
EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
FR2899486B1 (en) * | 2006-04-06 | 2008-07-04 | Lesors B V B A | IMPLANTABLE VENOUS INFUSION DEVICE |
WO2007143225A2 (en) | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
US20070299491A1 (en) * | 2006-06-22 | 2007-12-27 | Harshad Borgaonkar | Drug-eluting coating on shocking coil of tachy lead and methods related thereto |
JP2008126000A (en) * | 2006-11-24 | 2008-06-05 | Terumo Corp | Medical implement, medical apparatus and method of manufacturing medical implement |
US20080288017A1 (en) * | 2007-02-27 | 2008-11-20 | Cvrx, Inc. | External Baroreflex Activation |
US20200037875A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
CA2688184A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8594794B2 (en) | 2007-07-24 | 2013-11-26 | Cvrx, Inc. | Baroreflex activation therapy with incrementally changing intensity |
WO2009025817A2 (en) | 2007-08-20 | 2009-02-26 | Medtronic, Inc. | Evaluating therapeutic stimulation electrode configurations based on physiological responses |
US20090054947A1 (en) * | 2007-08-20 | 2009-02-26 | Medtronic, Inc. | Electrode configurations for directional leads |
US8295943B2 (en) | 2007-08-20 | 2012-10-23 | Medtronic, Inc. | Implantable medical lead with biased electrode |
US8190271B2 (en) * | 2007-08-29 | 2012-05-29 | Advanced Bionics, Llc | Minimizing trauma during and after insertion of a cochlear lead |
US8271101B2 (en) | 2007-08-29 | 2012-09-18 | Advanced Bionics | Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead |
US9452258B2 (en) | 2007-10-09 | 2016-09-27 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
WO2010002633A1 (en) * | 2008-07-03 | 2010-01-07 | Cardiac Pacemakers, Inc. | Helical fixation member with chemical elution capabilities |
US9801575B2 (en) | 2011-04-15 | 2017-10-31 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US20110125078A1 (en) * | 2009-11-25 | 2011-05-26 | Medtronic, Inc. | Optical stimulation therapy |
WO2012019036A1 (en) | 2010-08-06 | 2012-02-09 | Cardiac Pacemakers, Inc. | User interface system for use with multipolar pacing leads |
US8972028B2 (en) * | 2010-10-27 | 2015-03-03 | Dignity Health | Uterine electrical stimulation system and method |
US9872983B2 (en) | 2010-10-27 | 2018-01-23 | Dignity Health | Uterine electrical stimulation system and method |
US9592398B2 (en) | 2011-05-12 | 2017-03-14 | Medtronic, Inc. | Leadless implantable medical device with osmotic pump |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US20190120785A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3476116A (en) * | 1967-11-09 | 1969-11-04 | Victor Parsonnet | Nonpolarizing electrode for physiological stimulation |
US3568660A (en) * | 1967-11-20 | 1971-03-09 | Battelle Development Corp | Pacemaker catheter |
US3680544A (en) * | 1970-09-09 | 1972-08-01 | James P Shinnick | Transthoracic cannula-type device for cardiopulmonary resuscitation |
US3932656A (en) * | 1970-09-10 | 1976-01-13 | Alza Corporation | Article of manufacture for instant release of anti-aggregation and non-thrombogenic agents to biological media |
US3699956A (en) * | 1970-10-01 | 1972-10-24 | Tecna Corp | Percutaneous lead device |
CH557178A (en) * | 1972-08-10 | 1974-12-31 | Siemens Ag | DEVICE FOR DISPENSING DRUGS. |
US3829903A (en) * | 1972-12-11 | 1974-08-20 | Dow Corning | Method of inhibiting blood clot on silicone rubber medical devices |
US4033357A (en) * | 1975-02-07 | 1977-07-05 | Medtronic, Inc. | Non-fibrosing cardiac electrode |
US4055178A (en) * | 1976-03-10 | 1977-10-25 | Harrigan Roy Major | Drug delivery device for preventing contact of undissolved drug with the stomach lining |
GB1552388A (en) * | 1976-05-14 | 1979-09-12 | Macgregor D C | Cardiovascular prostheses |
DE2842318C2 (en) * | 1978-09-28 | 1985-05-23 | Siemens AG, 1000 Berlin und 8000 München | Implantable carbon electrode |
SU848004A1 (en) * | 1979-01-04 | 1981-07-23 | Всесоюзный Научно-Исследовательскийи Испытательный Институт Медицинскойтехники | Joining element for fixation of bone tissue |
-
1981
- 1981-09-01 CA CA000385012A patent/CA1174284A/en not_active Expired
- 1981-09-01 DE DE8181106829T patent/DE3173564D1/en not_active Expired
- 1981-09-01 EP EP81106829A patent/EP0047013B1/en not_active Expired
- 1981-09-01 JP JP1981130302U patent/JPS625174Y2/ja not_active Expired
-
1983
- 1983-03-31 US US06480913 patent/US4711251B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US4711251A (en) | 1987-12-08 |
JPS625174Y2 (en) | 1987-02-05 |
US4711251B1 (en) | 1994-06-28 |
EP0047013B1 (en) | 1986-01-22 |
JPS5770343U (en) | 1982-04-28 |
EP0047013A1 (en) | 1982-03-10 |
DE3173564D1 (en) | 1986-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1174284A (en) | Body implantable lead | |
US4606118A (en) | Method of making a drug dispensing body | |
USH356H (en) | Epicardial lead having low threshold, low polarization myocardial electrode | |
US4506680A (en) | Drug dispensing body implantable lead | |
US5041107A (en) | Electrically controllable, non-occluding, body implantable drug delivery system | |
US7667954B2 (en) | Capacitor | |
US6363286B1 (en) | High impedance electrode assembly | |
EP0422363B1 (en) | Screw-in drug eluting medical lead for implantation | |
US7684171B2 (en) | Capacitors based on valve metal alloys for use in medical devices | |
EP1552539B1 (en) | Capacitor and implantable medical device comprising such a capacitor | |
US5496360A (en) | Implantable cardiac electrode with rate controlled drug delivery | |
US5632770A (en) | Implantable defibrillation system with lead having improved porous surface coating | |
EP2108399B1 (en) | Implantable neuro-stimulation electrode with fluid reservoir | |
US7218971B2 (en) | Implantable lead with dissolvable coating for improved fixation and extraction | |
US7491246B2 (en) | Capacitor electrodes produced with atomic layer deposition for use in implantable medical devices | |
US5345933A (en) | Implantable medical device with a protected medication layer | |
US20110087317A1 (en) | Conductive polymeric coating with optional biobeneficial topcoat for a medical lead | |
CA2277930A1 (en) | Electrode for high impedance heart stimulation | |
JPH06312025A (en) | Human body stimulating/sensing lead, its electrode, and manufacture of said electrode | |
US6038482A (en) | Open bore electrode with a tiered drug therapy delivery system | |
JPH06190061A (en) | Electrode device for pacemaker | |
JP2010540105A (en) | Fibrous electrode material | |
US5562715A (en) | Cardiac pulse generator | |
CN109803720B (en) | Leadless stimulation device having a housing containing its internal components and functioning as a terminal for a battery case and an internal battery | |
US20080027526A1 (en) | Lead comprising a drug region shared by more than one electrode |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |